Resistance to aminoglycoside antibiotics is a serious problem,typically arising from inactivating enzymes, reduced uptake, or increasedefflux in the important pathogens for which they are used as treatment.Conjugating aminoglycosides to proline-rich antimicrobial peptides(PrAMPs), which also target ribosomes and have a distinct bacterialuptake mechanism, might mutually benefit their individual activities.To this aim we have developed a strategy for noninvasively modifyingtobramycin to link it to a Cys residue and through this covalentlylink it to a Cys-modified PrAMP by formation of a disulfide bond.Reduction of this bridge in the bacterial cytosol should release theindividual antimicrobial moieties. We found that the conjugation oftobramycin to the well-characterized N-terminal PrAMP fragment Bac7(1-35)resulted in a potent antimicrobial capable of inactivating not onlytobramycin-resistant bacterial strains but also those less susceptibleto the PrAMP. To a certain extent, this activity also extends to theshorter and otherwise poorly active fragment Bac7(1-15). Althoughthe mechanism that allows the conjugate to act when its individualcomponents do not is as yet unclear, results are very promising andsuggest this may be a way of resensitizing pathogens that have developedresistance to the antibiotic.
